Agenus Inc (STU:AJ8)
€ 7.952 0 (0%) Market Cap: 159.15 Mil Enterprise Value: 160.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Agenus Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 07:30PM GMT
Release Date Price: €25.02 (-12.46%)
Emily Bodnar
H.C. Wainwright & Co. - Analyst

Good afternoon, everyone. Thank you for joining us today. I'm pleased to introduce Garo Armen. He's the CEO and Chairman of Agenus.

Questions & Answers

Emily Bodnar
H.C. Wainwright & Co. - Analyst

Maybe to start, can you walk us through some of the key Agenus pipeline and some of the work you've done in the past 12 months? Maybe touch on some of your manufacturing capabilities.

Garo Armen
Agenus Inc. - Chairman & CEO

Certainly, I'm glad to do all of that. I'm happy to be here. As some of you may know, we are an immuno-oncology company whose tenure dates back about 30 years. In fact, it's 30 years, April. And we were founded with the objective that the immune system would be the holy grail to curing cancer. This was at a time when I use the term cure, people would look at me like I'm from a planet or something like that. And so here we are, 30 years later, with a substantial portfolio of products.

Now what's the purpose of these products?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot